CT colonography study demonstrates effectiveness of Medicsight CAD for colorectal cancer.

Medicsight plc presented a study demonstrating the effectiveness of Medicsight ColonCAD for the detection of colorectal cancer in symptomatic patients, at the European Congress of Radiology (ECR) in Vienna, Austria by Professor Steve Halligan from University College Hospital, London.

Professor Halligan has been investigating the relatively unexplored area of CAD detection for colorectal cancers in symptomatic patients. In his ECR presentation, Professor Halligan provided the preliminary results from an ongoing study investigating the potential for CAD to detect colon cancers demonstrated on CT colonography. Many other studies have shown the value of ColonCAD, and this study supports the expansion of the clinical usage of ColonCAD, which has increasingly been advocated for the detection of adenomatous polyps in asymptomatic patients.

The study investigated 59 patients, each with proven cancers established by colonoscopy and histology. These patients were examined with Medicsight ColonCAD to analyze paired prone and supine datasets over a range of four user adjustable CAD filter settings. Across the range of settings, ColonCAD detected 47 to 54 of the 59 cancers (sensitivity range of 88.7% – 91.5%).

Overall, the study showed Medicsight ColonCAD to be very effective in the detection of colon cancer on CT colonography. Both prone and supine datasets are required for optimal CAD results.

David Sumner, chief executive officer of Medicsight plc, commented, "We are pleased with the findings of this study focusing on colorectal cancers in symptomatic patients. These exciting preliminary results validate and could further extend the potential use of the Medicsight Colon CAD in clinical practice.